Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.

Abstract

Biomarkers have revolutionized scientific research on neurodegenerative diseases, in particular Alzheimer's disease, transformed drug trial design, and are also increasingly improving patient management in clinical practice. A few key cerebrospinal fluid biomarkers have been robustly associated with neurodegenerative diseases. Several novel biomarkers are very promising, especially blood-based markers. However, many biomarker findings have had low reproducibility despite initial promising results. In this perspective, we identify possible sources for low reproducibility of studies on fluid biomarkers for neurodegenerative diseases, with a focus on Alzheimer's disease. We suggest guidelines for researchers and journal editors, with the aim to improve reproducibility of findings.

• Authors: Niklas Mattsson-Carlgren, Sebastian Palmqvist, Kaj Blennow, Oskar Hansson
• Journal: Nature communications (Nat Commun) Vol. 11 Issue 1 Pg. 6252 (12 07 2020) ISSN: 2041-1723 [Electronic] England
• PMID: 33288742 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Amyloid beta-Peptides
• Biomarkers
• Peptide Fragments
• amyloid beta-protein (1-40)
• amyloid beta-protein (1-42)
• tau Proteins

Topics

• Alzheimer Disease (blood, cerebrospinal fluid, diagnosis)
• Amyloid beta-Peptides (blood, cerebrospinal fluid)
• Biomarkers (blood, cerebrospinal fluid)
• Humans
• Neurodegenerative Diseases (blood, cerebrospinal fluid, diagnosis)
• Peptide Fragments (blood, cerebrospinal fluid)
• Reproducibility of Results
• Sensitivity and Specificity
• tau Proteins (blood, cerebrospinal fluid)